Autolus Therapeutics plc (AUTL) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Autolus Therapeutics plc (AUTL) Earnings Overview
As of June 26, 2026, Autolus Therapeutics plc (AUTL) reported trailing twelve-month net income of -$289M, reflecting -24.1% year-over-year growth. The company earned $-1.09 per diluted share over the past four quarters, with a net profit margin of -381.4%.
Looking at the long-term picture, AUTL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2015.
Autolus Therapeutics plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), FATE (-$130M net income, -2051.1% margin), CRSP (-$569M net income, -16569.8% margin), AUTL has outperformed on profitability metrics. Compare AUTL vs KYMR →
AUTL Earnings vs Peers
Earnings metrics vs comparable public companies
AUTL Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$288M | -30.6% | -$281M | $-1.08 | -381.4% | -372.4% |
| 2024 | -$221M | -5.9% | -$241M | $-0.87 | -2180.5% | -2385.6% |
| 2023 | -$208M | -40.0% | -$180M | $-1.20 | -12272.3% | -10583.1% |
| 2022 | -$149M | -4.7% | -$143M | $-1.57 | -2403.0% | -2307.0% |
| 2021 | -$142M | -0.0% | -$140M | $-1.97 | -9429.1% | -9314.8% |
| 2020 | -$142M | -14.7% | -$303M | $-2.76 | -8285.4% | -17675.4% |
| 2019 | -$124M | -298.0% | -$248M | $-2.88 | -4258.9% | -8513.8% |
| 2018 | -$31M | -57.7% | -$58M | $-0.99 | -2976.5% | -5503.7% |
| 2017 | -$20M | -57.2% | -$23M | $-1.43 | -1165.2% | -1383.2% |
| 2016 | -$13M | -68.1% | -$14M | $-0.91 | -1035.5% | -1186.1% |
| 2015 | -$7M | - | -$8M | $-0.54 | -7931.1% | -8613.8% |
Download Data
Export AUTL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AUTL — Frequently Asked Questions
Quick answers to the most common questions about buying AUTL stock.
What is AUTL earnings per share (EPS)?
AUTL trailing twelve-month (TTM) diluted EPS is $-1.09, reflecting -24.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Autolus Therapeutics plc's net income?
Autolus Therapeutics plc (AUTL) trailing twelve-month net income is $-289M as of 2025. Earnings declined -24.1% year-over-year.
Is AUTL profitable?
AUTL is not currently profitable on a TTM basis, reporting a net loss of $-289M. Net margin is -381.4%. Investors should monitor for a return to profitability.
What is AUTL's earnings growth rate?
AUTL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are AUTL's profit margins?
Autolus Therapeutics plc net profit margin is -381.4%, operating margin is -372.4%, and gross margin is -27.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is -95.2%.
Is AUTL growing earnings?
AUTL earnings are declining — EPS fell -24.1% year-over-year. TTM net income dropped to $-289M. This contrasts with the 5-year CAGR of N/A.
What was AUTL's best earnings year?
Autolus Therapeutics plc's highest annual net income on record is $-7M, achieved in fiscal year 2015. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were AUTL's earnings last quarter?
AUTL's most recent reported quarter was Q1 2026. Net income was $-72M with diluted EPS of $-0.27. For a full breakdown of all quarters, see the quarterly earnings table on this page.